Advertisement

Cryopreservation of apheresis platelets treated with riboflavin and UV light

Published:September 19, 2022DOI:https://doi.org/10.1016/j.transci.2022.103580

      Abstract

      Background

      Pathogen reduction technology (PRT) is increasingly used in the preparation of platelets for therapeutic transfusion. As the Czech Republic considers PRT, we asked what effects PRT may have on the recovery and function of platelets after cryopreservation (CP), which we use in both military and civilian blood settings.

      Study design and methods

      16 Group O apheresis platelets units were treated with PRT (Mirasol, Terumo BCT, USA) before freezing; 15 similarly collected units were frozen without PRT as controls. All units were processed with 5–6% DMSO, frozen at − 80 °C, stored > 14 days, and reconstituted in thawed AB plasma. After reconstitution, all units were assessed for: platelet count, mean platelet volume (MPV), platelet recovery, thromboelastography, thrombin generation time, endogenous thrombin potential (ETP), glucose, lactate, pH, pO2, pCO2, HCO3, CD41, CD42b, CD62, Annexin V, CCL5, CD62P, and aggregates > 2 mm and selected units for Kunicki score.

      Results

      PRT treated platelet units had lower platelet number (247 vs 278 ×109/U), reduced thromboelastographic MA (38 vs 62 mm) and demonstrated aggregates compared to untreated platelets. Plasma coagulation functions were largely unchanged.

      Conclusions

      Samples from PRT units showed reduced platelet number, reduced function greater than the reduced number would cause, and aggregates. While the platelet numbers are sufficient to meet the European standard, marked platelets activation with weak clot strength suggest reduced effectiveness.

      Abbreviations:

      α angle (clot growth), C-CPs (untreated Control-cryopreserved platelet(s)), C-APs (untreated Control-fresh apheresis platelet(s)), CPs (cryopreserved platelet(s)), DMSO (dimethylsulfoxyide), ETP (endogenous thrombin potential), FACs (Flow cytometry), MA (maximum amplitude), MPV (mean platelet volume), PLTs (platelet(s)), PRT (pathogen reduction technology), Peak (maximum amount of thrombin formed), tPeak (maximal thrombin concentration in the sample), R (speed of cloth formation), SE (secondary electron), T-CPs (Treated cryopreserved platelet(s)), TEG (thromboelastography), T-APs (Fresh apheresis platelet(s) before PRT), T-PRAPs (Treated-fresh apheresis platelet(s)), TGT (thrombin generation time), tLag (lag-time before the beginning of accelerated thrombin production)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Badloe J.
        • Noorman J.
        The Netherlands experience with frozen −80C red cells, plasma and platelets in combat casualty care.
        Transfusion. 2011; 51: 24A
        • Holley A.
        • Marks D.C.
        • Johnson L.
        • et al.
        Frozen blood products: clinically effective and potentially ideal for remote Australia.
        Anaesth Intensive Care. 2013; 41: 10-19
        • Daly P.A.
        • Schiffer C.A.
        • Aisner J.
        • et al.
        Successful transfusion of platelets cryopreserved for more than 3 years.
        Blood. 1979; 54: 1023-1027
        • Bohonek M.
        • Kutac D.
        • Landova L.
        • Koranova M.
        • Sladkova E.
        • Staskova E.
        • et al.
        The use of cryopreserved platelets in the treatment of polytraumatic patients and patients with massive bleeding.
        Transfusion. 2019; 59: 1474-1478
        • Bohonek M.
        • Kutac D.
        • Acker J.P.
        • Seghatchian J.
        Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: an overview.
        Transfus Apher Sci. 2020; 59102754
        • Burnouf T.
        • Radosevich M.
        Reducing the risk of infection from plasma products: specific preventative strategies.
        Blood Rev. 2000; 14: 94-110
        • Ticehurst J.R.
        • Pisanic N.
        • Forman M.S.
        • et al.
        Probable transmission of hepatitis E virus (HEV) via transfusion in the United States.
        Transfusion. 2019; 59: 1024-1034
        • Dalton H.R.
        • Seghatchian J.
        Hepatitis E virus: emerging from the shadows in developed countries.
        Transfus Apher Sci. 2016; 55: 271-274
        • Busch M.P.
        • Kleinman S.H.
        • Nemo G.J.
        Current and emerging infectious risks of blood transfusions.
        J Am Med Assoc. 2003; 289: 959-962
        • Burnouf T.
        • Seghatchian J.
        Ebola virus convalescent blood products: where we are now and where we may need to go.
        Transfus Apher Sci. 2014; 51: 120-125
        • Prowse C.V.
        Component pathogen inactivation: a critical review.
        Vox Sang. 2013; 104: 183-199
        • Bohonek M.
        • Seghatchian J.
        Emergency supply policy of cryopreserved RBC and PLT: The Czech Republic concept.
        Transfus Apher Sci. 2020; 59102788
        • Rebulla P.
        The long and winding road to pathogen reduction of platelets, red blood cells and whole blood.
        Br J Haematol. 2019; 186: 655-667
        • Seghatchian J.
        • Putter J.S.
        Pathogen inactivation of whole blood and red cell components: an overview of concept, design, developments.
        Criteria Accept Storage Lesion Transfus Apher Sci. 2013; 49: 357-363
        • Perez-Pujol S.
        • Tonda R.
        • Lozano M.
        • Fuste B.
        • Lopez-Vilchez I.
        • Galan A.M.
        • et al.
        Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
        Transfusion. 2005; 45: 911-919
        • Mirasol Clinical Evaluation Study Group
        A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
        Transfusion. 2010; 50: 2362-2375
        • Seghatchian J.
        • Tolksdorf F.
        Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
        Transfus Apher Sci. 2012; 46: 221-229
        • Irsch J.
        • Seghatchian J.
        Update on pathogen inactivation treatment of plasma, with theINTERCEPT blood system: current position on methodological.
        Clin Regul Asp Transfus Apher Sci. 2015; 52: 240-244
        • Schlenke P.
        • Hervig T.
        • Isola H.
        • Wiesel M.L.
        • Kientz D.
        • Pinkoski L.
        • et al.
        Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers.
        Transfusion. 2008; 48: 697-705
        • Mohr H.
        • Gravemann U.
        • Müller T.H.
        Inactivation of pathogens in single units of therapeutic fresh plasma by irradiation with ultraviolet light.
        Transfusion. 2009; 49: 2144-2151
        • Hornsey V.S.
        • Drummond O.
        • Morrison A.
        • McMillan L.
        • MacGregor I.R.
        • Prowse C.V.
        Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins.
        Transfusion. 2009; 49: 2167-2172
        • Waters L.
        • Padula M.P.
        • Marks D.C.
        • Johnson L.
        Cryopreservation of UVC pathogen-inactivated platelets.
        Transfusion. 2019; 59: 2093-2102
        • Meinke S.
        • Wikman A.
        • Gryfelt G.
        • Hultenby K.
        • Uhlin M.
        • Höglund P.
        • et al.
        Cryopreservation of buffy coat-derived platelet concentrates photochemically treated with amotosalen and UVA light.
        Transfusion. 2018; 58: 2657-2668
        • Jimenez-Marco T.
        • Ballester-Servera C.
        • Quetglas-Oliver M.
        • Morell-Garcia D.
        • Torres-Reverte N.
        • Bautista-Gili A.M.
        • et al.
        Cryopreservation of platelets treated with riboflavin and UV light and stored at -80°C for 1 year.
        Transfusion. 2021; 61: 1235-1246
        • Valeri C.R.
        • Ragno G.
        • Khuri S.
        Freezing human platelets with 6 percent dimethyl sulfoxide with removal of the supernatant solution before freezing and storage at −80 degrees C without postthaw processing.
        Transfusion. 2005; 45: 1890-1891
      1. Council of Europe, Rec.No.R(95)15; Guide to the preparation, use and quality assurance of blood components. Decree of the Ministry of Health of Czech Republic No. 143/2008.

        • Kunicki T.J.
        • Tuccelli M.
        • Becker G.A.
        • Aster R.H.
        A study of variables affecting the quality of platelets stored at room temperature.
        Transfusion. 1975; 15: 414-421
        • Johnson L.
        • Coorey C.P.
        • Marks D.C.
        The hemostatic activity of cryopreserved platelets is mediated by phosphatidylserine-expressing platelets and platelet microparticles.
        Transfusion. 2014; 54: 1917-1926
      2. Council of Europe, Rec.No.R(20)20 Guide to the preparation, use and quality assurance of blood components.

        • Feys H.B.
        • Coene J.
        • Devloo R.
        • et al.
        Persistent aggregates in apheresis platelet concentrates.
        Vox Sang. 2015; 108: 368-377
        • Getz T.M.
        • Montgomery R.K.
        • Bynum J.A.
        • et al.
        Storage of platelets at 4_C in platelet additive solutions prevents aggregate formation and preserves platelet functional responses.
        Transfusion. 2016; 56: 1320-1328
      3. Decree of the Ministry of Health of Czech Republic No. 143/2008.